Price Alert: Shares of Second Sight Medical Products (EYES) Trade 5.19% Higher at Midday June 21
Equities Staff Follow |Second Sight Medical Products Inc (NASDAQ: EYES) shares climbed 5.19%, or $0.11 per share, as on 11:49:56 est today. Since opening the day at $2.05, 88,240 shares of Second Sight Medical Products exchanged hands and the stock has ranged between $2.30 and $2.12.
Already this year the company is up 30.06%.
Second Sight Medical Products anticipates its next earnings on 2022-08-11.
For technical charts, analysis, and more on Second Sight Medical Products visit the company profile.
About Second Sight Medical Products Inc
Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company's headquarters are in Los Angeles, California.
To get more information on Second Sight Medical Products Inc and to follow the company's latest updates, you can visit the company's profile page here: Second Sight Medical Products Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer